Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Iksuda Therapeutics
Iksuda Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
AbbVie and Gedeon Richter join forces to advance neuropsychiatric target R&D
The companies will aim to discover and progress targets for neuropsychiatric disorders
Containment in a high potent manufacturing facility
Throughout the pharmaceutical industry, there is a lack of consistency regarding the assignment of Occupational Exposure Limits (OELs) to specific bands
Rousselot
Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global...
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Causes and solutions for dark spots in tablet manufacturing
Natoli Engineering examines the causes and solutions for dark spots that can halt production
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
LegoChem and Iksuda expand ADC license agreement
In April 2020, Iksuda licensed global development and commercialisation rights for three ADC programmes using LCB's ADC linker/toxin platform
Finance
ADC developer Iksuda Therapeutics closes $47m financing round
The company’s lead preclinical candidate, IKS03, is a CD19-targeted ADC candidate for B-cell cancers
Research & Development
Iksuda releases first data on ADC efficacy on tumour regression
British next-gen Antibody Drug Conjugates developer says its IKS01 allows for the targeted delivery of a potent cytotoxic payload to tumours
Pharmaceutical
Iksuda and Femtogenix ink solid tumour agreement
Iksuda has stated it will use Femtogenix payload molecules to progress its lead antibody drug conjugate
Media
Glythera announces corporate name change and rebranding
Now the primary focus of Iksuda Therapeutics will be on the development of superior ADCs for treatment of difficult-to-treat cancers
Ingredients
Glythera appoints Professor Kerry Chester to SAB
Recruitment
Glythera appoints Chief Scientific Officer and strengthens SAB
Subscribe now